ReviewInternational journal of general medicine2026
Herpes Zoster in Aging Patients: Risk Factors and Prevention Strategies.
Review in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes zoster (HZ), also known as shingles, is caused by varicella-zoster virus reactivation and can lead to long-term complications such as postherpetic neuralgia (PHN). Risk of HZ and related complications increases with age, presence of chronic conditions, and immunosuppression. The United States (US) has an increasingly aging and multimorbid population; therefore, knowledge of risk factors and prevention opportunities for HZ are of critical importance to inform broad efforts to prevent this disease. To consolidate information on risk factors for adults aged ≥50 years and opportunities to address gaps in HZ prevention, a narrative review was conducted. In addition to well-known risk factors for HZ, such as immunocompromising conditions and immunosuppressive treatments, this review highlights risk factors less recognized in the existing literature. These risk factors (which include certain cardiovascular and chronic respiratory conditions, as well as diabetes, chronic kidney disease, end-stage kidney disease [ESKD], and multimorbidity) are pertinent to comprehensive preventive care. Several studies identified increased risks of adverse HZ outcomes, including PHN and functional decline during and following HZ episodes, in adults aged ≥50 years, with risk usually exacerbated by underlying medical conditions. Observational studies have shown that patients with HZ were at increased risk for certain acute cardiovascular disease events (e.g, major adverse cardiovascular events and post-herpetic cerebrovascular accidents), especially in the weeks and months following HZ. For US adults aged ≥50 years and immunocompromised adults aged ≥19 years, the recombinant zoster vaccine is recommended for the prevention of HZ by the Centers for Disease Control and Prevention. However, gaps in prevention remain. Opportunities exist to improve HZ prevention in adults aged ≥50 years, particularly among those with comorbidities, by expanding medical societies' dissemination tactics for vaccination guidelines and recommendations, and empowering specialists to both incorporate risk assessment into routine care and encourage vaccination guideline adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.